Vitamin D, Immune Modulation, and the Evolution of VDR Resistance:

Introduction

Vitamin D has one of the most paradoxical histories in medicine. Initially discovered as a life-saving factor against rickets, it later became the subject of intense controversy due to early reports of toxicity when administered in massive doses. For decades, this controversy shaped regulatory caution and clinical fear, reducing vitamin D to a narrow role in bone and calcium metabolism.

​

However, advances in immunology, molecular biology, and microbiome science now reveal that early conclusions were not wrong—but profoundly incomplete.

​

This article traces the historical evolution of vitamin D research, beginning with early high-dose experiments such as those of Steck (1937) and Slocumb (1940–42), progressing through the rediscovery of vitamin D as a steroid hormone, incorporating the Coimbra Protocol, and culminating in the LGS Protocol, which integrates gut biology, immune regulation, epigenetics, and VDR renewal through an anti-inflammatory diet.

​

The Early Era (1920s–1940s): Discovery, Enthusiasm, and Toxicity

Vitamin D as an “anti-rachitic factor”

​

In the early 20th century, vitamin D was identified as a fat-soluble factor capable of curing rickets. Its dramatic clinical effects led to widespread enthusiasm and rapid escalation of dosing—often using crude concentrates of activated ergosterol, with no understanding of pharmacokinetics, cofactors, or hormonal signaling.

At this stage:

• Vitamin D was not understood as a hormone

• There were no assays for 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, or PTH

• Calcium elevation was assumed to be the primary mechanism of action

This conceptual limitation would define the next phase.

​

The Steck and Slocumb Studies: What Was Really Observed

Steck et al. (1937): “Intoxication with Vitamin D” 

Steck and colleagues published Further Studies on Intoxication with Vitamin D in Annals of Internal Medicine (1937) to describe hypercalcemia, renal stress, and systemic symptoms occurring in patients exposed to extremely high, unstandardized doses of vitamin D.

Crucially, this was not a study designed to invalidate vitamin D therapy—it was a toxicity characterization study during an era when:

• Dosing reached hundreds of thousands to millions of IU daily

• Preparations varied wildly in potency

• No magnesium, vitamin K, or calcium regulation strategies existed

• Individual variability was unexplained

What Steck demonstrated was calcemic toxicity under uncontrolled conditions, not the failure of vitamin D as a therapeutic agent.

​

Slocumb (1940–42): A Synthesis Often Misread

Charles H. Slocumb later evaluated vitamin D in chronic infectious (rheumatoid/atrophic) arthritis. His work is frequently cited as evidence that vitamin D “does not work.”

A careful reading shows otherwise.

Key findings of significance:

• ~50–68% of patients experienced symptomatic improvement

• Improvement often occurred without requiring toxicity or hypercalcemia

• Renal changes were reversible when therapy was discontinued

• Toxicity was variable and individual-dependent

Slocumb’s real conclusion was not that vitamin D is ineffective, but that:

Vitamin D is not a specific agent and must be monitored carefully.

In modern terms, Slocumb unintentionally described heterogeneous VDR responsiveness without having the biological framework to explain it.

​

The Mid-Century Retreat: Vitamin D Reduced to Calcium

From the 1950s through the 1980s, the medical community reacted defensively:

• Vitamin D became framed primarily as a bone and calcium nutrient

• High-dose use was stigmatized

• Regulatory bodies adopted conservative RDAs

• Immune, neurologic, and endocrine effects were ignored

This retreat was not evidence-based restraint—it was conceptual oversimplification.

​

The Modern Rediscovery: Vitamin D as a Steroid Hormone

From the 1990s onward, science began to overturn prior assumptions.

Major paradigm shifts:

• Discovery of the Vitamin D Receptor (VDR) in:

  • T cells, B cells, macrophages, dendritic cells

  • Microglia and neurons

• Recognition that vitamin D regulates:

  • Innate immunity (cathelicidin, defensins)

  • Adaptive balance (Th1/Th17 suppression, Treg support)

  • Neuroimmune signaling

  • Mitochondrial and epigenetic pathways

Vitamin D was no longer a vitamin—it was a pleiotropic steroid hormone.

Yet a new problem emerged.

​

The Missing Piece: VDR Resistance in the Modern World

Despite adequate or even high serum vitamin D levels, many patients:

• Fail to respond clinically

• Develop inflammatory or autoimmune diseases

• Exhibit neuropsychiatric and neurodegenerative disorders

This paradox is explained by VDR Resistance, now increasingly prevalent due to modern lifestyle factors.

 

Primary drivers of VDR Resistance:

1. Ultra-processed diets

2. Loss of microbial diversity (gut dysbiosis)

3. Intestinal hyperpermeability (leaky gut)

4. Endotoxin (LPS) translocation

5. Chronic systemic inflammation

6. Autoimmune activation and neuroinflammation

 

This inflammatory milieu interferes with:

• VDR expression

• VDR nuclear translocation

• VDR–RXR binding

• Downstream gene transcription

As a result, vitamin D signaling becomes functionally blocked, regardless of dose.

​

Neuroinflammation and VDR Resistance

This same pathway explains the rising incidence of:

• ADHD / ADD

• Autism spectrum disorders

• Depression

• Schizophrenia

• Parkinson’s disease

• Alzheimer’s disease

All share:

• Gut–brain axis disruption

• Microglial activation

• Cytokine-driven neuroinflammation

• Impaired steroid hormone signaling

Vitamin D deficiency is often not the cause, but VDR dysfunction is the amplifier.

​

The Coimbra Protocol: A Critical Evolutionary Step

The Coimbra Protocol represented a major turning point by recognizing:

• Autoimmune disease requires higher vitamin D exposure

• Calcium metabolism must be tightly controlled

• PTH suppression is a functional marker of response

• Monitoring is non-negotiable

T

his protocol restored legitimacy to high-dose vitamin D therapy and corrected many safety concerns highlighted since the Steck era.

However, Coimbra primarily addresses:

• Calcium safety

• Immune suppression

It does not fully address why VDR resistance exists in the first place.

​

The LGS Protocol: VDR Renewal Through an Anti-Inflammatory Diet

The LGS Protocol (Leaky Gut Syndrome Protocol) represents the next and most comprehensive evolutionary step.

 

What makes the LGS Protocol fundamentally different

The LGS Protocol does not start with vitamin D dosing.

It starts with VDR renewal.

 

Core pillars of the LGS Protocol

1. Microbiome restoration

• Removal of ultra-processed foods

• Reduction of pathobionts

• Restoration of keystone taxa

• Support of SCFA production (butyrate)

 

2. Intestinal barrier repair

• Tight junction restoration

• Reduction of antigen translocation

• Decrease in systemic immune activation

 

3. Anti-inflammatory dietary signaling

• Nutritional inputs that actively de-repress VDR expression

• Reduction of NF-κB dominance

• Restoration of immune tolerance

 

4. Vitamin D as a signal, not a blunt tool

• Vitamin D dosing is individualized

• Response is assessed clinically and biologically

• Cofactors are mandatory

• The goal is functional VDR signaling, not a number

 

Why the LGS Protocol resolves the Steck–Slocumb paradox

What early researchers observed as:

• “Inconsistent benefit”

• “Transient response”

• “Toxicity in some but not others”

Is now understood as:

• Variable degrees of VDR resistance

• Unaddressed gut-immune dysfunction

• Absence of dietary and microbial signaling support

The LGS Protocol corrects the cause, not just the dose.

​​

Conclusion: From Dose-Centered Medicine to Receptor-Centered Biology

The history of vitamin D is not a story of failure.
It is a story of premature conclusions drawn from incomplete biology.

Early investigators such as Steck and Slocumb were correct in identifying real and clinically relevant risks associated with uncontrolled, massive dosing of vitamin D. Their observations of toxicity, variability, and transient responses were accurate within the scientific limits of their era. What they lacked were not clinical rigor or insight, but the biological tools necessary to interpret what they were seeing: immune signaling pathways, receptor biology, microbiome science, and the concept of systemic inflammatory resistance.

Mid-century medicine responded not by refining understanding, but by retreating—reducing vitamin D to a narrow role in calcium and bone metabolism and abandoning its broader physiological relevance. This retreat delayed progress for decades.

 

The Coimbra Protocol represented a critical corrective step. By reintroducing high-dose vitamin D within a framework of strict monitoring, calcium control, and individualized response assessment, it restored both safety and legitimacy to therapeutic vitamin D use, particularly in autoimmune disease. Coimbra demonstrated that vitamin D could be used powerfully and responsibly when physiology—not fear—guided practice.

​

Yet even Coimbra left an unanswered question:

Why do so many patients fail to respond adequately to vitamin D, even when dosing and monitoring are correct?

The answer lies in what modern medicine is only beginning to fully acknowledge:
vitamin D resistance is rarely a dosing problem — it is a signaling problem.

​

The LGS Protocol completes the evolutionary arc by shifting the clinical focus from how much vitamin D is given to whether the body is capable of receiving the signal. It introduces a decisive paradigm shift: VDR Renewal.

​

In the modern world, characterized by ultra-processed diets, chronic gut dysbiosis, intestinal hyperpermeability, endotoxemia, and persistent low-grade inflammation, VDR resistance has become the rule rather than the exception. This resistance underlies not only autoimmune disease, but a wide spectrum of systemic and neuroinflammatory conditions — including ADHD, autism spectrum disorders, depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease.

​

In these states, vitamin D deficiency is often secondary. The true pathology lies in a hostile biological terrain that suppresses receptor expression, impairs nuclear signaling, and distorts immune communication. In such a context, increasing the dose of vitamin D without restoring the terrain is analogous to increasing the volume of a message delivered to a disconnected receiver.

The LGS Protocol addresses this failure at its root.

​

By restoring gut integrity, correcting dysbiosis, reducing inflammatory signaling, and re-establishing immune tolerance through an anti-inflammatory, receptor-supportive diet, the LGS Protocol reopens the VDR signaling pathway. Vitamin D is no longer forced upon a resistant system; it is reintroduced into a biological environment capable of listening, responding, and regulating.

This reframes vitamin D not as a standalone treatment, but as a context-dependent biological signal — one that requires an intact interface between diet, microbiome, immune system, and genome.

​

The Future Direction of Medicine

The implications extend far beyond vitamin D.

Medicine is entering a receptor-centered era, where therapeutic success will no longer be defined by dose escalation, but by signal reception. The future of effective treatment lies in understanding and restoring the biological terrain that allows signaling molecules—hormones, nutrients, neurotransmitters, and immune mediators—to function as intended.

​

In this future:

• Deficiency will be distinguished from resistance

• Symptoms will be traced to signaling failure, not isolated organ pathology

• Diet and the microbiome will be recognized as upstream regulators of genomic expression

• Chronic disease will be approached as a systems-level communication breakdown

Vitamin D stands as one of the clearest examples of this transition.

It does not heal in isolation.
It heals when the terrain allows the receptor to listen.

And that terrain — in autoimmunity, neuroinflammation, and chronic disease — begins in the gut.

​